News

TScan Therapeutics Announces Presentations at Upcoming Industry Conferences

September 14, 2020

WALTHAM, MA – TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced that management will present virtually at the following upcoming industry conferences:

H.C. Wainwright 22nd Annual Global Investment Conference

  • David Southwell, Chief Executive Officer, will present a company overview on September 14, 2020, at 12:30 p.m. Eastern Time

CAR-TCR Digital Week

  • Gavin MacBeath, Ph.D., Chief Scientific Officer, will present “TScan, a Whole Genome, Unbiased Approach to Cancer Target Discovery” on September 14, 2020, at 1:45 p.m. Eastern Time

American Society of Gene and Cell Therapy (ASGCT) COVID-19 Symposium

  • Dr. MacBeath will present the poster “Unbiased Genome-Wide Discovery Using TScan Reveals Shared Immunodominant CD8+ T Cell Epitopes in SARS-COV-2” in an oral session on September 16, 2020, at 5:00 p.m. Eastern Time

TCR-based Therapies Summit

  • Dr. MacBeath will lead the seminar “Expanding TCR Therapy by Identifying New Targets and TCRs from Patient TILs” on October 28, 2020, at 9:00 a.m. Eastern Time

About TScan Therapeutics
TScan discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors, and other serious diseases. Our proprietary, high-throughput platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of highly efficacious TCR-Ts with minimal off-target effects. Lead program TSC-100 is expected to enter clinical development for liquid cancers in 2021, and the Company is advancing additional TCR-Ts for solid cancers. TScan was co-founded by Chair Christoph Westphal (Partner, Longwood Fund) based on pioneering research from the Elledge Lab at Brigham and Women’s Hospital. The Company has raised over $80 million to date from leading strategic collaborators and investors including Longwood Fund, Novartis Institutes for Biomedical Research, Astellas Venture Management, Novartis Venture Fund, Bessemer Venture Partners, GV, 6 Dimensions Capital, and Pitango Venture Capital.